Last reviewed · How we verify
placebo + fluoxetine
Fluoxetine selectively inhibits serotonin reuptake in the brain, increasing serotonin availability at synapses to improve mood and reduce depressive symptoms.
Fluoxetine selectively inhibits serotonin reuptake in the brain, increasing serotonin availability at synapses to improve mood and reduce depressive symptoms. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | placebo + fluoxetine |
|---|---|
| Sponsor | University of Florida |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake transporter for serotonin, prolonging serotonin's presence in the synaptic cleft. This enhanced serotonergic neurotransmission is thought to alleviate symptoms of depression and anxiety. The placebo component in this formulation serves as a control or comparative element in clinical research.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Bulimia nervosa
- Premenstrual dysphoric disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Sexual dysfunction
- Diarrhea
- Tremor
- Anxiety
Key clinical trials
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Fluoxetine and Understanding Social Experiences (NA)
- Fluoxetine on Emotional Experience (FLEX) Study (NA)
- Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV (PHASE2)
- Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study (PHASE2)
- SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project (NA)
- Dapagliflozin in Depression (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo + fluoxetine CI brief — competitive landscape report
- placebo + fluoxetine updates RSS · CI watch RSS
- University of Florida portfolio CI